Evidence map›Paper›PMID 35869542›Full record

ArticleJournal of cannabis research2022

Anti-cancer properties of cannflavin A and potential synergistic effects with gemcitabine, cisplatin, and cannabinoids in bladder cancer.

Andrea M Tomko, Erin G Whynot, Denis J Dupré

Open access · goldAbstract read
In one paragraph

Article in Journal of cannabis research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Charting the Cannabis plant chemical space with computational metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2024
    Article
  11. The Use of Compounds Derived fromInternational journal of molecular sciences · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Anticancer properties of cannabidiol and ΔJournal of cannabis research · 2023
    Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Andrea M TomkoFaculty of Medicine, Department of Pharmacology, Dalhousie University, PO BOX 15 000, Sir Charles Tupper Medical Building, 5850 College St., Halifax, NS, B3H 4R2, Canada.
Erin G WhynotFaculty of Medicine, Department of Pharmacology, Dalhousie University, PO BOX 15 000, Sir Charles Tupper Medical Building, 5850 College St., Halifax, NS, B3H 4R2, Canada.
Denis J DupréFaculty of Medicine, Department of Pharmacology, Dalhousie University, PO BOX 15 000, Sir Charles Tupper Medical Building, 5850 College St., Halifax, NS, B3H 4R2, Canada. denis.dupre@dal.ca.ORCID http://orcid.org/0000-0001-6401-6157
Dalhousie University · CA

Funding

Beatrice Hunter Cancer Research Institute CRTP training awardBladder Cancer Canada CUASF-BCC Research grantFaculty of Medicine, Dalhousie University Dept Pharmacology graduate bursary
6 · The paper itself

Abstract

introductionSeveral studies have shown anti-tumor effects of components present in cannabis in different models. Unfortunately, little is known about the potential anti-tumoral effects of most compounds present in cannabis in bladder cancer and how these compounds could potentially positively or negatively impact the actions of chemotherapeutic agents. Our study aims to evaluate the effects of a compound found in Cannabis sativa that has not been extensively studied to date, cannflavin A, in bladder cancer cell lines. We aimed to identify whether cannflavin A co-treatment with agents commonly used to treat bladder cancer, such as gemcitabine and cisplatin, is able to produce synergistic effects. We also evaluated whether co-treatment of cannflavin A with various cannabinoids could produce synergistic effects.

methodsTwo transitional cell carcinoma cell lines were used to assess the cytotoxic effects of the flavonoid cannflavin A up to 100 μM. We tested the potential synergistic cytotoxic effects of cannflavin A with gemcitabine (up to 100 nM), cisplatin (up to 100 μM), and cannabinoids (up to 10 μM). We also evaluated the activation of the apoptotic cascade using annexin V and whether cannflavin A has the ability to reduce invasion using a Matrigel assay.

resultsCell viability of bladder cancer cell lines was affected in a concentration-dependent fashion in response to cannflavin A, and its combination with gemcitabine or cisplatin induced differential responses-from antagonistic to additive-and synergism was also observed in some instances, depending on the concentrations and drugs used. Cannflavin A also activated apoptosis via caspase 3 cleavage and was able to reduce invasion by 50%. Interestingly, cannflavin A displayed synergistic properties with other cannabinoids like Δ DISCUSSION: Our results indicate that compounds from Cannabis sativa other than cannabinoids, like the flavonoid cannflavin A, can be cytotoxic to human bladder transitional carcinoma cells and that this compound can exert synergistic effects when combined with other agents. In vivo studies will be needed to confirm the activity of cannflavin A as a potential agent for bladder cancer treatment.

Indexed as

ApoptosisBladder cancerCannabichromeneCannabidiolCannabivarinCannflavin ACisplatinGemcitabineInvasionΔ9-Tetrahydrocannabinol

Identifiers

PMID35869542
PMCPMC9306207
OpenAlexW4286433042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.